Close Menu
    Trending
    • Abu Dhabi signs four OpenAI deals as Sheikh Khaled meets Altman
    • Indonesia posts $10.6 billion trade surplus on non-oil exports
    • Shudao Investment Group Shines at the Global Panda Partners Conference 2026
    • Modaxo Welcomes Fiscaltech
    • XPENG Showcases New Flagship SUVs and Physical AI Ecosystem in Dubai as MEA Expansion Accelerates
    • Artprice by Artmarket Enters into Dialogue with the Entire Spanish-Speaking World and Throws Open the Doors of the Global South with AI and the Status of the Author
    • Lexani Motorcars Unveils Lexus LX600 Bespoke Luxury Interior
    • Africa’s top banks build war chest for Kenya takeover deals
    • Home
    • Contact Us
    Doha ReportDoha Report
    Tuesday, November 3
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Doha ReportDoha Report
    Home » Innovative experimental malaria drug based on antibodies discovered
    Featured News

    Innovative experimental malaria drug based on antibodies discovered

    November 1, 2022
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    A new study in Africa has found that a one-time dose of an experimental drug protects adults against malaria for at least six months. In 2020, malaria killed more than 620,000 people and sickened 241 million, mostly children under 5. There is a malaria vaccine being rolled out by the World Health Organization for children, but it is only 30% effective and requires four doses.

    Innovative experimental malaria drug based on antibodies discoveredIn this new study, people received a large dose of lab-made malaria-fighting antibodies instead of relying on the immune system to make enough of those same infection-blockers after vaccination, reported the Associated Press (AP). “There are not enough people protected by the vaccine available,” said Kassoum Kayentao, a researcher from the University of Sciences, Techniques and Technologies in Bamako, Mali.

    In those villages, people are bitten by infected mosquitoes on average twice a day during malaria season, according to other research. Experimental antibody, developed by researchers at the US National Institutes of Health, was delivered by IV. In the meantime, an easy-to-administer shot version from the same scientists is in early testing in infants, children, and adults.

    Research presented at a medical meeting in Seattle was published Monday in the New England Journal of Medicine. In order to work, the antibody breaks the life cycle of the parasite, which is spread through mosquito bites. It targets immature parasites before they mature and multiply in the liver. An antibody taken from a volunteer who received a malaria vaccine was used to develop it.

    It involved 330 adults in Mali who received either a dummy infusion or two different antibody doses. Every two weeks for 24 weeks, all were tested for malaria infection. Treatment was provided to anyone who became ill. A blood test detected infections in 20 people who received the higher dose, 39 people who received the lower dose, and 86 people who received the placebo. Compared to the placebo, the higher dose was 88% effective. There was a 75% effectiveness rate for the lower dose.

    During a malaria season, protection might last for several months. In the future, it could be used in conjunction with other malaria prevention methods, such as malaria pills, mosquito nets, and vaccinations. According to one estimate, lab-made antibodies could be given for as little as $5 per child per malaria season.

    Related Posts

    Gulf Medical University Ranked 1st for International Student Ratio in QS Arab Region Rankings 2027

    October 22, 2026

    IGNITE Launches MENA Platform in Dubai, Bringing Together Entrepreneurship, AI-Powered Learning and Global Consumer Brands

    October 12, 2026

    Dataroid Recognized in the Gartner® Market Guide for Product Analytics (2026)

    October 6, 2026

    Wibmo Fraud & Risk Management wins Chartis Disruptor Award for its Agentic Risk Intelligence Solution

    September 28, 2026

    VitrA Tiles Introduces “The Code” concept and the New Codes of Design at Cersaie Fair

    September 25, 2026

    Plast Eurasia invites Middle East buyers for its 35th edition

    September 21, 2026
    Breaking News

    Abu Dhabi signs four OpenAI deals as Sheikh Khaled meets Altman

    November 3, 2026

    – Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, met Sam Altman, CEO of OpenAI, on Monday to explore opportunities for advancing cooperation in artificial intelligence. Following

    Indonesia posts $10.6 billion trade surplus on non-oil exports

    November 3, 2026

    Africa’s top banks build war chest for Kenya takeover deals

    November 3, 2026

    UAE President and Bavaria’s Söder discuss expanding cooperation

    November 3, 2026

    Apple iPhone Duo review: an engineering triumph for foldables

    November 2, 2026

    Bangladesh dengue deaths reach 418 after deadliest month of 2026

    November 2, 2026

    South Korea’s exports hit record $115.3 billion on chip boom

    November 2, 2026

    iPhone Duo review: Apple’s first foldable weighs its trade-offs

    November 2, 2026
    © 2026 Doha Report | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.